Home » Stocks » REXN

Rexahn Pharmaceuticals, Inc. (REXN)

Nov 5, 2020 - Stock symbol was changed to OCUP
Stock Price: $1.81 USD -0.06 (-3.21%)
Updated Nov 5, 2020 4:00 PM EST

REXN Stock Price Chart

Key Info

Market Cap 2.03M
Revenue (ttm) 1.15M
Net Income (ttm) -6.37M
Shares Out 4.24M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 5, 2020
Last Price $1.81
Previous Close $1.87
Change ($) -0.06
Change (%) -3.21%
Day's Open -
Day's Range 1.72 - 1.93
Day's Volume 0
52-Week Range 1.70 - 3.70

REXN Stock News

GlobeNewsWire - 4 weeks ago

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is ...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Re...

PRNewsWire - 5 months ago

NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphir...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (...

GlobeNewsWire - 5 months ago

Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates

About REXN

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang ... [Read more...]

Industry
Biotechnology
CEO
Douglas J. Swirsky
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
REXN
Full Company Profile

Financial Performance

Financial Statements